Endurant Capital Management LP / OCUL
Endurant Capital Management LP’s Ocular Therapeutix Inc Position
Does Endurant Capital Management LP own Ocular Therapeutix Inc (OCUL)? Not currently — the last reported position was 353.7K shares worth $1M in Q3 2023; the fund’s latest 13F (Q1 2024) no longer reports it.
Position Value
$1M
Q3 2023
Shares
353.7K
% of Portfolio
+1.00%
Quarters Held
16
position exited
Position History OCUL
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q3 2023 | 353.7K | $1M | +1.00% |
| Q2 2023 | 368.4K | $2M | +1.66% |
| Q1 2023 | 512.7K | $3M | +1.39% |
| Q4 2022 | 1.06M | $3M | +1.21% |
| Q3 2022 | 1.06M | $4M | +1.44% |
| Q2 2022 | 760.2K | $3M | +1.07% |
| Q1 2022 | 924.0K | $5M | +1.20% |
| Q4 2021 | 717.1K | $5M | +1.21% |
| Q3 2021 | 610.4K | $6M | +1.39% |
| Q2 2021 | 571.0K | $8M | +2.23% |
| Q1 2021 | 438.9K | $7M | +1.88% |
| Q4 2020 | 290.5K | $6M | +2.17% |
| Q3 2020 | 837.1K | $6M | +1.88% |
| Q2 2020 | 755.3K | $6M | +0.34% |
| Q1 2019 | 716.1K | $3M | +1.12% |
| Q4 2018 | 232.7K | $926,000 | +0.49% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Endurant Capital Management LP’s full portfolio or all institutional holders of OCUL.